287 related articles for article (PubMed ID: 20347511)
21. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
Toussaint ND; Lau KK; Polkinghorne KR; Kerr PG
Nephrology (Carlton); 2011 Mar; 16(3):290-8. PubMed ID: 21342323
[TBL] [Abstract][Full Text] [Related]
22. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial.
Zein CO; Jorgensen RA; Clarke B; Wenger DE; Keach JC; Angulo P; Lindor KD
Hepatology; 2005 Oct; 42(4):762-71. PubMed ID: 16175618
[TBL] [Abstract][Full Text] [Related]
23. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Dogra G; Irish A; Chan D; Watts G
Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
26. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
[TBL] [Abstract][Full Text] [Related]
27. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
Toussaint ND; Elder GJ; Kerr PG
Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
[TBL] [Abstract][Full Text] [Related]
29. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
Jamal SA; Bauer DC; Ensrud KE; Cauley JA; Hochberg M; Ishani A; Cummings SR
J Bone Miner Res; 2007 Apr; 22(4):503-8. PubMed ID: 17243862
[TBL] [Abstract][Full Text] [Related]
30. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
31. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial.
Cortés-Sanabria L; Cabrera-Pivaral CE; Cueto-Manzano AM; Rojas-Campos E; Barragán G; Hernández-Anaya M; Martínez-Ramírez HR
Am J Kidney Dis; 2008 May; 51(5):777-88. PubMed ID: 18436088
[TBL] [Abstract][Full Text] [Related]
32. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
33. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
Mehrotra R
J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial of pulsatile perfusion using an intra-aortic balloon pump versus nonpulsatile perfusion on short-term changes in kidney function during cardiopulmonary bypass during myocardial reperfusion.
Onorati F; Presta P; Fuiano G; Mastroroberto P; Comi N; Pezzo F; Tozzo C; Renzulli A
Am J Kidney Dis; 2007 Aug; 50(2):229-38. PubMed ID: 17660024
[TBL] [Abstract][Full Text] [Related]
35. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
36. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
[TBL] [Abstract][Full Text] [Related]
37. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
[TBL] [Abstract][Full Text] [Related]
38. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
39. Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial.
Cianciaruso B; Pota A; Bellizzi V; Di Giuseppe D; Di Micco L; Minutolo R; Pisani A; Sabbatini M; Ravani P
Am J Kidney Dis; 2009 Dec; 54(6):1052-61. PubMed ID: 19800722
[TBL] [Abstract][Full Text] [Related]
40. Impact of intradialytic exercise on arterial compliance and B-type natriuretic peptide levels in hemodialysis patients.
Toussaint ND; Polkinghorne KR; Kerr PG
Hemodial Int; 2008 Apr; 12(2):254-63. PubMed ID: 18394060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
